We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Occidental Petroleum
OXY
$57B
| $8.93M | 0.12% |
200,766
+66,541
| +50% | +$3.15M |
|
202
Jones Lang LaSalle
JLL
$15.1B
| $8.86M | 0.12% |
63,689
+48,128
| +309% | +$6.67M |
|
203
Credicorp
BAP
$30.9B
| $8.61M | 0.11% |
41,300
-45,200
| -52% | -$9.79M |
|
204
CEVA Inc
CEVA
$1.01B
| $8.51M | 0.11% |
284,827
-52,372
| -16% | -$1.53M |
|
205
Southern Copper
SCCO
$141B
| $8.48M | 0.11% |
268,060
-77,128
| -22% | -$2.45M |
|
|
BOLD
206
DELISTED
Audentes Therapeutics, Inc
BOLD
| $8.45M | 0.11% |
300,800
| – | – |
|
|
SPPI
207
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $8.44M | 0.11% |
1,017,400
-50,000
| -5% | -$404K |
|
208
Ambarella
AMBA
$2.99B
| $8.4M | 0.11% |
133,677
-61,282
| -31% | -$3.18M |
|
209
PACCAR
PCAR
$69.6B
| $8.4M | 0.11% |
179,967
+6,343
| +4% | +$289K |
|
210
Regions Financial
RF
$26.3B
| $8.39M | 0.11% |
530,631
+58,497
| +12% | +$884K |
|
|
IRBT
211
DELISTED
iRobot
IRBT
| $8.36M | 0.11% |
+135,508
| New | +$9.7M |
|
|
VAR
212
DELISTED
Varian Medical Systems, Inc.
VAR
| $8.34M | 0.11% |
70,036
+25,509
| +57% | +$3.03M |
|
|
SJR
213
DELISTED
Shaw Communications Inc.
SJR
| $8.28M | 0.11% |
421,288
+310,030
| +279% | +$6.11M |
|
214
Zebra Technologies
ZBRA
$12.4B
| $8.27M | 0.11% |
40,053
-13,629
| -25% | -$2.75M |
|
215
Williams Companies
WMB
$90.5B
| $8.23M | 0.11% |
342,103
+31,512
| +10% | +$794K |
|
|
B
216
Barrick Mining
B
$62.2B
| $8.14M | 0.11% |
470,403
+2,644
| +0.6% | +$46.7K |
|
217
Freeport-McMoran
FCX
$90B
| – | – |
-33,324
| Closed | -$342K |
|
218
Take-Two Interactive
TTWO
$43B
| $8.08M | 0.11% |
64,486
+10,794
| +20% | +$1.35M |
|
|
QIWI
219
DELISTED
QIWI PLC
QIWI
| $8.03M | 0.11% |
366,000
+25,000
| +7% | +$540K |
|
220
Supernus Pharmaceuticals
SUPN
$2.68B
| $8.02M | 0.11% |
292,000
+7,000
| +2% | +$207K |
|
221
Oneok
OKE
$58.7B
| $7.95M | 0.11% |
107,858
-222
| -0.2% | -$15.7K |
|
|
EIDX
222
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $7.88M | 0.1% |
219,000
-104,000
| -32% | -$4.06M |
|
223
Mercado Libre
MELI
$91.3B
| $7.87M | 0.1% |
14,271
-21,358
| -60% | -$13M |
|
224
Synchrony
SYF
$23.7B
| $7.86M | 0.1% |
230,405
-12,051
| -5% | -$413K |
|
225
Automatic Data Processing
ADP
$100B
| $7.84M | 0.1% |
48,552
+613
| +1% | +$101K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.